Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Disclosures: Teresa J. Melink and John C. Gutheil, Proacta employees. The remaining authors declare no competing financial interests.

Contributions: M.K., T.M., J.G., E.E., H.K. conceived of and designed the study, acquired and interpreted the data, and drafted the manuscript; P.T. and H.N. conceived statistical design and analyzed the data; Y.G. and W.W. performed and analyzed the pharmacokinetic assays; C.-A. Y. analyzed the data and drafted the manuscript; G.B., A.C., F.R., E.J., S.F., D.T., J.C., T.K, S.K., N.D., N.P., J.F., acquired the data; C. B.-R., J.B., D. K., H.L. performed biomarker assessments; W. C. analyzed the data; and all authors critically reviewed, commented on, and approved the final manuscript.